Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Aprea Therapeutics

Aprea Therapeutics
Regional

Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen

November 19, 2025November 17, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported third-quarter 2025 financial results and highlighted steady progress across its two clinical-stage DNA damage response (DDR) programs, citing emerging signs of …

Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen Read More

Aprea Therapeutics
Regional

Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial

October 31, 2025October 30, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced encouraging early clinical data from its ongoing Phase 1 ACESOT-1051 trial evaluating APR-1051, a first-in-class WEE1 kinase inhibitor, in patients with …

Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial Read More
Aprea Therapeutics
Regional

Aprea Therapeutics to Present New Data on APR-1051 and ATRN-119 at EORTC-NCI-AACR Conference

October 21, 2025October 19, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that new data from its ongoing oncology programs will be featured in two poster presentations at the 2025 EORTC-NCI-AACR International Conference …

Aprea Therapeutics to Present New Data on APR-1051 and ATRN-119 at EORTC-NCI-AACR Conference Read More

Aprea Therapeutics
Regional

Aprea Reports Positive Early Cancer Trial Results, Maintains Cash Runway Into 2026

August 14, 2025August 12, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported encouraging early clinical results from its two lead oncology programs while narrowing its quarterly loss, according to second-quarter 2025 financial results …

Aprea Reports Positive Early Cancer Trial Results, Maintains Cash Runway Into 2026 Read More
Aprea Therapeutics
Regional

Aprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive Cancers

June 26, 2025June 25, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has revealed new preclinical findings and a clinical update on APR-1051, an innovative oral WEE1 inhibitor being studied for the treatment of …

Aprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive Cancers Read More

Aprea Therapeutics
Regional

Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing

April 2, 2025April 1, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the first patient with HPV-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) …

Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing Read More
Aprea Therapeutics
Regional

Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations

March 26, 2025March 26, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, shared its financial results for 2024 and provided a progress update on its lead programs aimed at advancing cancer …

Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations Read More

Aprea Therapeutics
Regional

Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research

March 13, 2025March 12, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center to advance preclinical studies of its WEE1 kinase inhibitor, APR-1051. …

Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research Read More
Aprea Therapeutics
Regional

Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation

February 6, 2025February 5, 2025 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced significant advancements in its intellectual property portfolio, reinforcing the company’s leadership in the development of DNA Damage Response (DDR) therapeutics for …

Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation Read More
Aprea Therapeutics
Regional

Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing

December 13, 2024December 11, 2024 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) has announced a key update in its ongoing Phase 1/2a ABOYA-119 clinical trial for ATRN-119, aimed at treating advanced solid tumors with DNA damage …

Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing Read More

Posts pagination

1 2 Next

Trending News

  • CubeSmart Extends Dividend Growth Run With Fresh Quarterly Boost

  • Shopping Center Theft Probe Leads to Drug-Related Arrest in Bucks County

  • Gas Station Encounter Sparks Hunt for Wanted Driver After Alleged High-Speed Escape

  • A Night of Chaos: Crashes, Chases, and Arrests Mark Busy Day for Wyomissing Police

  • The Record Company to Celebrate 10th Anniversary of GRAMMY®-Nominated Debut with Show at Union Transfer

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Joseph Holod

Shopping Center Theft Probe Leads to Drug-Related Arrest in Bucks County

December 23, 2025December 23, 2025

James Joseph Obyrne

Gas Station Encounter Sparks Hunt for Wanted Driver After Alleged High-Speed Escape

December 23, 2025December 23, 2025

Police News

A Night of Chaos: Crashes, Chases, and Arrests Mark Busy Day for Wyomissing Police

December 23, 2025December 23, 2025

Copyright © 2025 MyChesCo.